Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
Open Access
- 12 May 2021
- journal article
- research article
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 7
Abstract
Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.Keywords
This publication has 13 references indexed in Scilit:
- Viral myocarditisCurrent Opinion in Rheumatology, 2016
- Miocarditis mortal por enterovirus asociada a tratamiento de linfoma folicular con rituximab y quimioterapiaMedicina Clinica, 2013
- Myocarditis and diffuse skeletal muscle oedema: new features of neuromyelitis optica spectrum disorder? A case reportMultiple Sclerosis Journal, 2013
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesEuropean Heart Journal, 2013
- Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndromePediatric Nephrology, 2013
- The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseasesBritish Journal of Haematology, 2010
- Tolerability and safety of rituximab (MabThera®)Cancer Treatment Reviews, 2005
- Coxsackievirus-induced myocarditis: new trends in treatmentExpert Review of Anti-infective Therapy, 2005
- The group B coxsackieviruses and myocarditisReviews in Medical Virology, 2001
- The organisms reported to cause myocarditis and pericarditis in England and WalesJournal of Infection, 1996